Overall, she said, the campaign is part of Abbott’s work to “chip away” at the obstacles facing people with diabetes as they seek out proper care and treatment. It builds on the stigma ...

In a report released today, Lee Hambright from Bernstein downgraded Tandem Diabetes Care (TNDM – Research Report) to a Hold, with a price ...

Above the Bias, Abbott’s minute-long spot, seeks to address the shame, guilt and misconceptions that often surround diabetes. The short film also delves into how this bias can deter patients from ...

Medtronic ( MDT -0.99%) and Abbott Laboratories ( ABT -1.91%) are two such examples in the healthcare industry. Both are ...

As for earnings, ABT’s fourth-quarter fiscal 2024 earnings report showed sales growth of 9.5% for the year (excluding COVID ...

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Tandem Diabetes Care (TNDM – Research Report) yesterday and set a price ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Abbott Laboratories. If we consider the ...

Abbott's ABT diversified business portfolio is well-positioned to drive momentum. However, the international business ...

Abbott had claimed that the shape of Sinocare ... “The judgments also reinforce the importance of consumer choice in diabetes care, ensuring that advanced CGM solutions remain accessible ...

DexCom's growth is slowing with 2024 marking the slowest growth year in a decade and 2025 expected to follow suit with ~14% ...

Good day and welcome to the Tandem Diabetes Fourth Quarter and Year-End 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there ...

Analysts have recently evaluated Abbott Laboratories and provided 12-month price targets. The average target is $145.12, ...